GLP-1-based therapies interrupt early cardiovascular risk pathways in obesity, improving HFpEF outcomes
Interruption of Early Cardiovascular Risk Pathways With GLP-1-Based Therapy for Obesity.
Abstract
GLP-1-based therapies for obesity converge on multiple biological pathways, reducing systemic inflammation and congestion to improve cardiovascular outcomes in HFpEF.